[1]谷巍,宋光耀,李晓龙.肾脏异位脂质沉积与糖尿病肾脏病脂毒性机制的研究进展[J].国际内分泌代谢杂志,2022,42(03):199-202.[doi:10.3760/cma.j.cn121383-20210324-03067]
　Gu Wei,Song Guangyao,Li Xiaolong..Research progress of renal ectopic lipid deposition and the mechanism of lipid toxicity in diabetic kidney disease[J].International Journal of Endocrinology and Metabolism,2022,42(03):199-202.[doi:10.3760/cma.j.cn121383-20210324-03067]
点击复制

肾脏异位脂质沉积与糖尿病肾脏病脂毒性机制的研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年03期
页码:
199-202
栏目:
综述
出版日期:
2022-05-20

文章信息/Info

Title:
Research progress of renal ectopic lipid deposition and the mechanism of lipid toxicity in diabetic kidney disease
作者:
谷巍1; 宋光耀2; 李晓龙1
1衡水市人民医院内分泌代谢科 053000; 2河北省人民医院内分泌代谢科,石家庄 050000
Author(s):
Gu Wei1;  Song Guangyao2;  Li Xiaolong1.
1Department of Endocrinology, Hengshui People's Hospital, Hengshui 053000; 2Department of Endocrinology, Hebei General Hospital, Shijiazhuang 050000
关键词:
糖尿病肾脏病;  异位脂质沉积;  脂毒性
Keywords:
Diabetic kidney disease;  Ectopic lipid deposition;  Toxicity of fat
DOI:
10.3760/cma.j.cn121383-20210324-03067
摘要:
糖尿病肾脏病是常见的糖尿病微血管并发症之一。研究发现早期糖尿病肾脏病患者肾内就已发现有异位脂质沉积,其可引起肾内细胞发生脂毒性损伤。异位脂质沉积主要与脂肪酸摄取、氧化利用失衡及脂代谢紊乱有关。本文从异位脂质沉积导致肾脏结构改变、肾内异位脂质沉积形成以及其形成后导致肾脏受损诱发糖尿病肾脏病最新机制进行了详细阐述,同时就基于上述机制进行的治疗进行了总结,为糖尿病肾脏病治疗提供了新的方向。
Abstract:
Diabetic kidney disease is one of the common diabetic microvascular complications. In patients with early diabetic kidney disease, ectopic lipid deposition has been found in the kidney, which can cause lipotoxic damage to renal cells. It has been found that ectopic lipid deposition is mainly related to fatty acid uptake, oxidation imbalance and lipid metabolism disorder. In this paper, the latest mechanism of ectopic lipid deposition leading to changes in renal structure and function, the formation of ectopic lipid deposition in the kidney, and its formation leading to kidney damage and diabetic kidney disease are described in detail, and the treatment based on the above mechanism is also discussed. In conclusion, it provides a new direction for the treatment of diabetic kidney disease.

参考文献/References:

[1] Vejakama P,Ingsathit A,McKay GJ,et al.Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients[J].BMC Nephrol,2017,18(1):342.DOI:10.1186/s12882-017-0753-9.
[2] Wang YC,Feng Y,Lu CQ,et al.Renal fat fraction and diffusion tensor imaging in patients with early-stage diabetic nephropathy[J].Eur Radiol,2018,28(8):3326-3334.DOI:10.1007/s00330-017-5298-6.
[3] Nunes S,Alves A,Preguiça I,et al.Crescent-Like lesions as an early signature of nephropathy in a rat model of prediabetes induced by a hypercaloric diet[J].Nutrients,2020,12(4):881.DOI:10.3390/nu12040881.
[4] Longo M,Zatterale F,Naderi J,et al.Adipose tissue dysfunction as determinant of Obesity-Associated metabolic complications[J].Int J Mol Sci,2019,20(9):2358.DOI:10.3390/ijms20092358.
[5] Nishi H,Higashihara T,Inagi R.Lipotoxicity in kidney,heart,and skeletal muscle dysfunction[J].Nutrients,2019,11(7):1664.DOI:10.3390/nu11071664.
[6] Wahl P,Ducasa GM,Fornoni A.Systemic and renal lipids in kidney disease development and progression[J].Am J Physiol Renal Physiol,2016,310(6):F433-445.DOI:10.1152/ajprenal.00375.2015.
[7] Zhang Z,Ni L,Zhang L,et al.Empagliflozin regulates the AdipoR1/p-AMPK/p-ACC pathway to alleviate lipid deposition in diabetic nephropathy[J].Diabetes Metab Syndr Obes,2021,14:227-240.DOI:10.2147/DMSO.S289712.
[8] Yang W,Luo Y,Yang S,et al.Ectopic lipid accumulation:potential role in tubular injury and inflammation in diabetic kidney disease[J].Clin Sci(Lond),2018,132(22):2407-2422.DOI:10.1042/CS20180702.
[9] Herman-Edelstein M,Scherzer P,Tobar A,et al.Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy[J].J Lipid Res,2014,55(3):561-572.DOI:10.1194/jlr.P040501.
[10] Iwai T,Kume S,Chin-Kanasaki M,et al.Stearoyl-CoA Desaturase-1 Protects Cells against Lipotoxicity-Mediated Apoptosis in Proximal Tubular Cells[J].Int J Mol Sci,2016,17(11):1868.DOI:10.3390/ijms17111868.
[11] Sun H,Yuan Y,Sun Z,et al.Update on mechanisms of renal tubule injury caused by advanced glycation end products[J].Biomed Res Int,2016,2016:5475120.DOI:10.1155/2016/5475120.
[12] Fu Y,Sun Y,Wang M,et al.Elevation of JAML Promotes Diabetic Kidney Disease by Modulating Podocyte Lipid Metabolism[J].Cell Metab,2020,32(6):1052-1062.e8.DOI:10.1016/j.cmet.2020.10.019.
[13] Du C,Wu M,Liu H,et al.Thioredoxin-interacting protein regulates lipid metabolism via Akt/mTOR pathway in diabetic kidney disease[J].Int J Biochem Cell Biol,2016,79:1-13.DOI:10.1016/j.biocel.2016.08.006.
[14] Suzuki S,Yokoyama A,Noro E,et al.Expression and pathophysiological significance of carbohydrate response element binding protein(ChREBP)in the renal tubules of diabetic kidney[J].Endocr J,2020,67(3):335-345.DOI:10.1507/endocrj.EJ19-0133.
[15] Chen N,Mu L,Yang Z,et al.Carbohydrate response element-binding protein regulates lipid metabolism via mTOR complex1 in diabetic nephropathy[J].J Cell Physiol,2021,236(1):625-640.DOI:10.1002/jcp.29890.
[16] Gai Z,Gui T,Hiller C,et al.Farnesoid X receptor protects against kidney injury in uninephrectomized obese mice[J].J Biol Chem,2016,291(5):2397-2411.DOI:10.1074/jbc.M115.694323.
[17] Wang XX,Levi J,Luo Y,et al.SGLT2 protein expression is increased in human diabetic nephropathy:SGLT2 protein inhibition decreases renal lipid accumulation,inflammation,and the development of nephropathy in diabetic mice[J].J Biol Chem,2017,292(13):5335-5348.DOI:10.1074/jbc.M117.779520.
[18] 陈绵雄,林慧,张菊云,等.脂联素通过抑制RIP1/RIP3表达对糖尿病肾病小鼠肾脏的保护作用[J].山西医科大学学报,2020,51(9):938-943.DOI:10.13753/j.issn.1007-6611.2020.09.010.
[19] Chen Y,He L,Yang Y,et al.The inhibition of Nrf2 accelerates renal lipid deposition through suppressing the ACSL1 expression in obesity-related nephropathy[J].Ren Fail,2019,41(1):821-831.DOI:10.1080/0886022X.2019.1655450.
[20] Son JH,Yoo HH,Kin DH,et al.Activation of de novo synthetic pathway of ceramides is responsible for the initiation of hydrogen peroxide-induced apoptosis in HL-60 cells[J].J Toxicol Environ Health A,2007,70(15-16):1310-1318.DOI:10.1080/15287390701434364.
[21] 李渐鹏,杜方岭,闫永恒,等.甘油二酯对2型糖尿病肾病大鼠肾脏保护机制[J].营养学报,2016,(38)02:147-151.
[22] Kong Y,Zhao X,Qiu M,et al.Tubular Mas receptor mediates lipid-induced kidney injury[J].Cell Death Dis,2021,12(1):110.DOI:10.1038/s41419-020-03375-z.
[23] Xie Z,Zhong L,Wu Y,et al.Carnosic acid improves diabetic nephropathy by activating Nrf2/ARE and inhibition of NF-κB pathway[J].Phytomedicine,2018,47:161-173.DOI:10.1016/j.phymed.2018.04.031.
[24] Jiang X,Yu J,Wang X,et al.Quercetin improves lipid metabolism via SCAP-SREBP2-LDLr signaling pathway in early stage diabetic nephropathy[J].Diabetes Metab Syndr Obes,2019,12:827-839.DOI:10.2147/DMSO.S195456.
[25] Park HS,Lim JH,Kim MY,et al.Resveratrol increases AdipoR1 and AdipoR2 expression in type 2 diabetic nephropathy[J].J Transl Med,2016,14(1):176.DOI:10.1186/s12967-016-0922-9.
[26] Xu M,Jiang F,Li B,et al.1α,25(OH)2D3 alleviates high glucose-induced lipid accumulation in rat renal tubular epithelial cells by inhibiting SREBPs[J].J Cell Biochem,2019,120(9):15211-15221.DOI:10.1002/jcb.28786.
[27] Su K,Yi B,Yao BQ,et al.Liraglutide attenuates renal tubular ectopic lipid deposition in rats with diabetic nephropathy by inhibiting lipid synthesis and promoting lipolysis[J].Pharmacol Res,2020,156:104778.DOI:10.1016/j.phrs.2020.104778.
[28] Hosokawa K,Takata T,Sugihara T,et al.Ipragliflozin ameliorates endoplasmic reticulum stress and apoptosis through preventing ectopic lipid deposition in renal tubules[J].Int J Mol Sci,2019,21(1):190.DOI:10.3390/ijms21010190.
[29] Tanaka Y,Kume S,Araki S,et al.Fenofibrate,a PPARαagonist,has renoprotective effects in mice by enhancing renal lipolysis.Kidney Int,2011,79(8):871-882.DOI:10.1038/ki.2010.530.

相似文献/References:

[1]中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏病防治指南(2021年版)[J].国际内分泌代谢杂志,2021,41(04):388.[doi:10.3760/cma.j.cn121383-20210825-08064]
　Microvascular Complications Group of Chinese Diabetes Society.Clinical guideline for the prevention and treatment of diabetic kidney disease in China(2021 edition)[J].International Journal of Endocrinology and Metabolism,2021,41(03):388.[doi:10.3760/cma.j.cn121383-20210825-08064]
[2]高忠爱,杨波,郑妙艳,等.糖尿病合并大量蛋白尿的中西医治疗策略[J].国际内分泌代谢杂志,2021,41(06):583.[doi:10.3760/cma.j.cn121383-20210930-09088]
　Gao Zhongai,Yang Bo,Zheng Miaoyan,et al.Treatment strategies of traditional Chinese and western medicine in diabetic patients with overt proteinuria[J].International Journal of Endocrinology and Metabolism,2021,41(03):583.[doi:10.3760/cma.j.cn121383-20210930-09088]
[3]黄婧荷,宋焱,郭立新.糖尿病肾脏病的磁共振成像评估方法及进展[J].国际内分泌代谢杂志,2023,43(04):309.[doi:10.3760/cma.j.cn121383-20220403-04007]
　Huang Jinghe,Song Yan,Guo Lixin.Magnetic resonance imaging in diabetic kidney disease:assessment and update[J].International Journal of Endocrinology and Metabolism,2023,43(03):309.[doi:10.3760/cma.j.cn121383-20220403-04007]

备注/Memo

备注/Memo:
通信作者:宋光耀,Email:sguangyao2@163.com
更新日期/Last Update: 2022-05-10